[en] Objective: Currently, there is no effective medical treatment for patients with pituitary-dependent Cushing’s disease. A novel somatostatin (SS) analogue, named SOM230, with high binding affinity to SS receptor subtypes sst1, sst2, sst3 and sst5 was recently introduced. We compared the in vitro effects of the sst2-preferring SS analogue octreotide (OCT) and the multi-ligand SOM230 on ACTH release by human and mouse corticotroph tumour cells.
Methods: By quantitative RT-PCR the sst subtype expression level was determined in human corticotroph adenomas. In vitro, the inhibitory effect of OCT and SOM230 on ACTH release by dispersed human corticotroph adenoma cells and mouse AtT20 corticotroph adenoma cells was determined. In addition, the influence of dexamethasone on the responsiveness to OCT and SOM230 was studied.
Results: Corticotroph adenomas expressed predominantly sst5 mRNA (six out of six adenomas), whereas sst2 mRNA expression was detected at significantly lower levels. In a 72 h incubation with 10 nmol/l SOM230, ACTH release was inhibited in three out of five cultures (range –30 to –40%). Ten nmol/l OCT slightly inhibited ACTH release in only one of five cultures (– 28%). In AtT20 cells, expressing sst2, sst3 and sst5, SOM230 inhibited ACTH secretion with high potency (IC50 0.2 nmol/l). Dexamethasone (10 nmol/l) pre-treatment did not influence the sensitivity of the cells to the inhibitory effect of SOM230, suggesting that sst5 is relatively resistant to negative control by glucocorticoids.
Conclusions: The selective expression of sst5 receptors in corticotroph adenomas and the preferential inhibition of ACTH release by human corticotroph adenoma cells by SOM230 in vitro, suggest that SOM230 may have potential in the treatment of patients with pituitary-dependent Cushing’s disease.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Hofland, Leo J.
van der Hoek, Joost
Feelders, Richard
van Aken, Maarten O.
van Koetsveld, Peter M.
Waaijers, Marlijn
Sprij-Mooij, Diana
Bruns, Christian
Weckbecker, Gisbert
de Herder, Wouter W.
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Lamberts, Steven W. J.
Language :
English
Title :
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B & Lombardi G. New medical approaches in pituitary adenomas. Hormone Research 2000 53 76-87.
Morris D & Grossman A. The medical management of Cushing's syndrome. Annals of the New York Academy of Sciences 2002 970 119-133.
Miller JW & Crapo L. The medical treatment of Cushing's syndrome. Endocrine Reviews 1993 14 443-458.
De Herder WW, Kwekkeboom DJ, Reys AEM, Kooy PPM, Hofland L, Krenning E & Lamberts SW. Receptor scintigraphy with somatostatin analogues and dopamine antagonists of pituitary tumours. In Pituitary Adenomas. From Basic Research to Diagnosis and Therapy, pp 93-104. Eds K von Werder & R Fahlbush. Amsterdam: Elsevier Science BV, 1996.
Lamberts SW, Uitterlinden P & Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinologica 1989 120 760-766.
De Herder WW & Lamberts SW. Octapeptide somatostatin-analogue therapy of Cushing's syndrome. Postgraduate Medical Journal 1999 75 65-66.
Lamberts SW, De Herder WW, Krenning EP & Reubi JC. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1994 78 17-19.
Tyrrell JB, Lorenzi M, Gerich JE & Forsham PH. Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. Journal of Clinical Endocrinology and Metabolism 1975 40 1125-1127.
Newell-Price J, Trainer P, Besser M & Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocrine Reviews 1998 19 647-672.
Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J & Mutter OA. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. European Journal of Endocrinology 1994 130 125-131.
Day R, Dong W, Panetta R, Kraicer J, Greenwood MT & Patel YC. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology 1995 136 5232-5235.
Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT & Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1995 80 1386-1392.
Panetta R & Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 1995 56 333-342.
Greenman Y & Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph line-age. Journal of Clinical Endocrinology and Metabolism 1994 79 724-729.
Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Astrup J, Weeke J & Jorgensen JO. Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 2997-3000.
Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 2002 146 707-716.
Weckbecker G, Briner U, Lewis I & Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002 143 4123-4130.
Oosterom R, Blaauw G, Singh R, Verleun T & Lamberts SW. Isolation of large numbers of dispersed human pituitary adenoma cells obtained by aspiration. Journal of Endocrinological Investigation 1984 7 307-311.
Hofland LJ, Van Der Hoek J, Van Koetsveld PM, De Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, Van Der Lely AJ, Beekers A & Lamberts SW. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 1577-1585.
Hofland LJ, Lamberts SW, Van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, Van Koetsveld PM, Srinivasan A, Krenning EP & Breeman WA. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. Journal of Nuclear Medicine 2003 44 1315-1321.
Hofland LJ, Van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA & Lamberts SW. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology 1995 136 3698-3706.
Ferone D, Van Hagen PM, Van Koetsveld PM, Zuijderwijk J, Mooy DM, Lichtenauer-Kaligis EG, Colao A, Bogers AJ, Lombardi G, Lamberts SW & Holland LJ. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999 140 373-380.
Richardson UI & Schonbrunn A. Inhibition of adrenocorticotropin secretion by somatostatin in pituitary cells in culture. Endocrinology 1981 108 281-290.
Richardson UI. ACTH secretion in mouse pituitary tumor cells in culture: inhibition of CRF-stimulated hormone release by somatostatin. Life Sciences 1983 33 1981-1988.
Litvin Y, Leiser M, Fleischer N & Erlichman J. Somatostatin inhibits corticotropin-releasing factor-stimulated adrenocorticotropin release, adenylate cyclase, and activation of adenosine 3′,5′-monophosphate-dependent protein kinase isoenzymes in AtT20 cells. Endocrinology 1986 119 737-745.
Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G & Bruns C. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. Journal of Medicinal Chemistry 2003 46 2334-2344.
Brown MR, Rivier C & Vale W. Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology 1984 114 1546-1549.
Kraicer J, Gajewski TC & Moor BC. Release of pro-opiomelanocortin-derived peptides from the pars intermedia and pars distalis of the rat pituitary: effect of corticotrophin-releasing factor and somatostatin. Neuroendocrinology 1985 41 363-373.
Nicholson SA, Adrian TE, Gillham B, Jones MT & Bloom SR. Effect of hypothalamic neuropeptides on corticotrophin release from quarters of rat anterior pituitary gland in vitro. Journal of Endocrinology 1984 100 219-226.
Voight KH, Fehm HL, Lang RE & Walter R. The effect of somatostatin and of prolyl-leucyl-glycinamide (MIF) on ACTH release in dispersed pituitary cells. Life Sciences 1977 21 739-745.
Lamberts SW, Zuyderwijk J, Den Holder F, Van Koetsveld P & Hofland L. Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 1989 50 44-50.
Ambrosi B, Bochicchio D, Fadin C, Colombo P & Faglia G. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. Journal of Endocrinological Investigation 1990 13 257-261.
Benker G, Hackenberg K, Hamburger B & Reinwein D. Effects of growth hormone release-inhibiting hormone and bromocriptine (CB 154) in states of abnormal pituitary-adrenal function. Clinical Endocrinology 1976 5 187-190.
Fehm HL, Voigt KH, Lang R, Beinert KE, Raptis S & Pfeiffer EF. Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klinische Wochenschrift 1976 54 173-175.
Suda T, Tomori N, Tozawa F, Demura H & Shizume K. Effects of corticotropin-releasing factor and other materials on adrenocorticotropin secretion from pituitary glands of patients with Cushing's disease in vitro. Journal of Clinical Endocrinology and Metabolism 1984 59 840-845.
Spada A, Reza-Elahi F, Lania A, Bassetti M & Atti E. Inhibition of basal and corticotropin-releasing hormone-stimulated adenylate cyclase activity and cytosolic Ca2+ levels by somatostatin in human corticotropin-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1990 70 1262-1268.
Shibasaki T, Nakahara M, Shizume K, Kiyosawa Y, Suda T, Demura H, Kuwayama A, Kageyama N, Benoit R & Ling N. Pituitary adenomas that caused Cushing's disease or Nelson's syndrome are not responsive to ovine corticotropin-releasing factor in vitro. Journal of Clinical Endocrinology and Metabolism 1983 56 414-416.
Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 1982 110 1147-1154.
O'Carroll AM & Krempels K. Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endocrinology 1995 136 5224-5227.
Greenman Y & Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1994 78 398-403.
Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M, Astrup J, Weeke J & Jorgensen JO. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. Journal of Endocrinological Investigation 2001 24 430-437.
Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E & Hoyer D. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. British Journal of Pharmacology 2003 139 109-121.
Strowski MZ, Dashkevicz MP, Parmar RM, Wilkinson H, Kohler M, Schaeffer JM & Blake AD. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 2002 75 339-346.
George SR, Kovacs K, Asa SL, Horvath E, Cross EG & Burrow GN. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma. Clinical Endocrinology 1987 26 395-405.
Lamberts SW, Verleun T, Hofland L & Del Pozo E. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Clinical Endocrinology 1987 27 11-23.
Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, Gopal-Truter S, Fisher JK, Schaeffer JM, Blake AD, Zhang BB & Wilkinson HA. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Molecular Endocrinology 2003 17 93-106.
Reisine T. Somatostatin desensitization: loss of the ability of somatostatin to inhibit cyclic AMP accumulation and adrenocorticotropin hormone release. Journal of Pharmacology and Experimental Therapeutics 1984 229 14-20.
Reisine TD & Takahashi JS. Somatostatin pretreatment desensitizes somatostatin receptors linked to adenylate cyclase and facilitates the stimulation of cyclic adenosine 3′,5′-monophosphate accumulation in anterior pituitary tumor cells. Journal of Neuroscience 1984 4 812-819.
Heisler S & Srikant CB. Somatostatin-14 and somatostatin-28 pretreatment down-regulate somatostatin-14 receptors and have biphasic effects on forskolin-stimulated cyclic adenosine, 3′,5′-monophosphate synthesis and adrenocorticotropin secretion in mouse anterior pituitary tumor cells. Endocrinology 1985 117 217-225.
Stroh T, Jackson AC, Sarret P, Dal Farra C, Vincent JP, Kreienkamp HJ, Mazella J & Beaudet A. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology 2000 141 354-365.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
